News
Hosted on MSN5mon
Sonnet BioTherapeutics to expand trial of SON-1010 with ... - MSNUS-based biotechnology company Sonnet BioTherapeutics has expanded its Phase I SB101 study of SON-1010 for advanced solid tumours.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback